PT2033629E - Composição farmacêutica sólida que compreende valsartan - Google Patents

Composição farmacêutica sólida que compreende valsartan

Info

Publication number: PT2033629E
Authority: PT; Portugal
Prior art keywords: valsartan; pharmaceutical composition; solid pharmaceutical; solid; composition
Prior art date: 2004-12-24

Application number

PT81656316T

Other languages

English (en)

Inventor

Marija Rangus

Miha Vrbinc

Silvo Zupancic

Janika Slanc Vovk

Franci Bevec

Lidija Cernosa

Original Assignee

Krka

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-24

Filing date

2005-12-23

Publication date

2013-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35966966&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2033629(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-24 Priority claimed from EP04030782A external-priority patent/EP1674080A1/en

2005-12-23 Application filed by Krka filed Critical Krka

2013-01-24 Publication of PT2033629E publication Critical patent/PT2033629E/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PT81656316T 2004-12-24 2005-12-23 Composição farmacêutica sólida que compreende valsartan PT2033629E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04030782A EP1674080A1 (en)	2004-12-24	2004-12-24	Solid pharmaceutical composition comprising valsartan
EP05004433		2005-03-01

Publications (1)

Publication Number	Publication Date
PT2033629E true PT2033629E (pt)	2013-01-24

Family

ID=35966966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT81656316T PT2033629E (pt)	2004-12-24	2005-12-23	Composição farmacêutica sólida que compreende valsartan

Country Status (16)

Country	Link
US (1)	US20080102120A1 (pt)
EP (2)	EP2033629B1 (pt)
CN (1)	CN101087589B (pt)
AU (1)	AU2005318365B2 (pt)
CA (1)	CA2592091A1 (pt)
DK (1)	DK2033629T3 (pt)
EA (2)	EA015108B1 (pt)
ES (1)	ES2397552T3 (pt)
HR (1)	HRP20130033T1 (pt)
ME (1)	ME01453B (pt)
NO (1)	NO20073889L (pt)
PL (1)	PL2033629T3 (pt)
PT (1)	PT2033629E (pt)
RS (1)	RS52607B (pt)
SI (1)	SI2033629T1 (pt)
WO (1)	WO2006066961A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20081364A1 (es) *	2006-09-04	2008-12-04	Novartis Ag	Composicion farmaceutica que comprende valsartan
EP1897537A1 (en) *	2006-09-04	2008-03-12	Novartis AG	Composition comprising an angiotensin II receptor antagonist
US20080152717A1 (en) *	2006-12-14	2008-06-26	Isp Investments, Inc.	Amorphous valsartan and the production thereof
TR200703568A1 (tr) *	2007-05-24	2008-07-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Valsartan formülasyonları
GB0715628D0 (en) *	2007-08-10	2007-09-19	Generics Uk Ltd	Solid valsartan composition
WO2009113091A2 (en) *	2008-01-24	2009-09-17	Usv Limited	Pharmaceutical compositions comprising valsartan
WO2010104485A2 (en) *	2009-03-11	2010-09-16	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Valsartan formulations
WO2011102702A2 (en)	2010-02-16	2011-08-25	Krka, D. D., Novo Mesto	Process for the preparation of oral solid dosage forms comprising valsartan
CN102119912A (zh) *	2011-01-25	2011-07-13	南京白敬宇制药有限责任公司	一种非水溶性药物缓释制剂的制备方法
CN102204907A (zh) *	2011-03-31	2011-10-05	北京赛科药业有限责任公司	一种含缬沙坦的药物组合物及其制备方法
WO2013098576A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) *	2013-11-22	2018-10-30	威海迪素制药有限公司	一种降压组合物
KR101545268B1 (ko)	2015-02-05	2015-08-20	보령제약 주식회사	정제 및 이의 제조방법
CN104887640B (zh) *	2015-06-30	2017-12-19	昆明医科大学	一种含有缬沙坦的固体药物组合物
US20210267908A1 (en) *	2020-03-02	2021-09-02	Mankind Pharma Ltd.	Pharmaceutical compositions of rivaroxaban
CN112098408B (zh) *	2020-09-14	2022-12-09	湖北亿纬动力有限公司	一种羧甲基纤维素钠溶解效果的检测方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0443983T3 (da)	1990-02-19	1996-03-18	Ciba Geigy Ag	Acrylforbindelser
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
SK9132001A3 (en)	1998-12-23	2002-01-07	Novartis Ag	Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6211217B1 (en) *	1999-03-16	2001-04-03	Novartis Ag	Method for reducing pericardial fibrosis and adhesion formation
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU2001273938B2 (en) *	2000-04-12	2005-03-03	Novartis Ag	Novel medical use of aldosterone synthase inhibitors alone or in combination with ati-receptor antagonists
US6499984B1 (en) *	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation
SK18062002A3 (sk)	2000-06-22	2003-07-01	Novartis Ag	Pevné orálne farmaceutické kompozície obsahujúce valsartan
IL153882A0 (en) *	2000-07-19	2003-07-31	Novartis Ag	Valsartan salts
US20030152622A1 (en) *	2001-10-25	2003-08-14	Jenny Louie-Helm	Formulation of an erodible, gastric retentive oral diuretic
ATE370732T1 (de)	2002-01-17	2007-09-15	Novartis Pharma Gmbh	Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
CN1726030A (zh) *	2002-12-18	2006-01-25	诺瓦提斯公司	缬沙坦与cox－2抑制剂的组合
CA2519490A1 (en)	2003-03-17	2004-09-30	Teva Pharmaceutical Industries Ltd	Polymorphis of valsartan
EP1556363A2 (en)	2003-04-21	2005-07-27	Teva Pharmaceutical Industries Limited	Process for the preparation of valsartan and intermediates thereof
US7378531B2 (en) *	2003-04-21	2008-05-27	Teva Pharmaceutical Industries Ltd	Process for the preparation of valsartan
US7915247B1 (en) *	2006-08-21	2011-03-29	Mutual Pharmaceutical Company, Inc.	Methods of use of fenofibric acid

2005
- 2005-12-23 EA EA200900646A patent/EA015108B1/ru not_active IP Right Cessation
- 2005-12-23 WO PCT/EP2005/013963 patent/WO2006066961A1/en active Application Filing
- 2005-12-23 CA CA002592091A patent/CA2592091A1/en not_active Abandoned
- 2005-12-23 EP EP08165631A patent/EP2033629B1/en not_active Revoked
- 2005-12-23 EP EP20050824409 patent/EP1833464A1/en not_active Withdrawn
- 2005-12-23 AU AU2005318365A patent/AU2005318365B2/en not_active Ceased
- 2005-12-23 PL PL08165631T patent/PL2033629T3/pl unknown
- 2005-12-23 DK DK08165631.6T patent/DK2033629T3/da active
- 2005-12-23 PT PT81656316T patent/PT2033629E/pt unknown
- 2005-12-23 RS RS20120564A patent/RS52607B/en unknown
- 2005-12-23 EA EA200701107A patent/EA012392B1/ru not_active IP Right Cessation
- 2005-12-23 SI SI200531638T patent/SI2033629T1/sl unknown
- 2005-12-23 US US11/794,039 patent/US20080102120A1/en not_active Abandoned
- 2005-12-23 ME MEP-2012-149A patent/ME01453B/me unknown
- 2005-12-23 CN CN2005800447851A patent/CN101087589B/zh not_active Expired - Fee Related
- 2005-12-23 ES ES08165631T patent/ES2397552T3/es active Active
2007
- 2007-07-24 NO NO20073889A patent/NO20073889L/no not_active Application Discontinuation
2013
- 2013-01-16 HR HRP20130033TT patent/HRP20130033T1/hr unknown

Also Published As

Publication number	Publication date
WO2006066961A1 (en)	2006-06-29
CN101087589B (zh)	2013-01-30
HRP20130033T1 (hr)	2013-02-28
NO20073889L (no)	2007-09-24
SI2033629T1 (sl)	2013-01-31
ME01453B (me)	2014-04-20
EP2033629B1 (en)	2012-11-14
PL2033629T3 (pl)	2013-04-30
RS52607B (en)	2013-04-30
ES2397552T3 (es)	2013-03-07
EA012392B1 (ru)	2009-10-30
CN101087589A (zh)	2007-12-12
DK2033629T3 (da)	2013-02-04
EP1833464A1 (en)	2007-09-19
EP2033629A1 (en)	2009-03-11
AU2005318365A1 (en)	2006-06-29
AU2005318365B2 (en)	2011-02-03
EA200900646A1 (ru)	2009-10-30
US20080102120A1 (en)	2008-05-01
EA015108B1 (ru)	2011-06-30
CA2592091A1 (en)	2006-06-29
EA200701107A1 (ru)	2008-04-28

Publication	Publication Date	Title
PL2033629T3 (pl)	2013-04-30	Stała kompozycja farmaceutyczna zawierająca walsartan
IL177480A0 (en)	2006-12-10	Pharmaceutical composition
IL223545A0 (en)	2013-02-03	Pharmaceutical compositions
IL179809A0 (en)	2007-05-15	Pharmaceutical compositions
GB0408308D0 (en)	2004-05-19	Pharmaceutical compositions
EP1871347A4 (en)	2012-10-31	PHARMACEUTICAL COMPOSITION
PL1837019T3 (pl)	2013-02-28	Kompozycja farmaceutyczna rozpadająca się w ustach
IL183986A0 (en)	2007-10-31	Pharmaceutical compounds and compositions
EP1805154A4 (en)	2009-11-25	PHARMACEUTICAL COMPOSITIONS
EP1937255A4 (en)	2013-06-26	PHARMACEUTICAL COMPOSITION
ZA200705131B (en)	2008-06-25	Solid pharmaceutical composition comprising valsartan
EP1862184A4 (en)	2012-12-19	PHARMACEUTICAL COMPOSITION
HU0401177D0 (en)	2004-08-30	Pharmaceutical composition
IL180316A0 (en)	2007-07-04	Quinolone-containing medicinal composition
GB2411355B (en)	2006-02-22	Pharmaceutical composition
ZA200701932B (en)	2008-08-27	Pharmaceutical composition
GB0425255D0 (en)	2004-12-15	Pharmaceutical composition
ZA200701931B (en)	2008-10-29	Pharmaceutical composition
HUP0401176A2 (en)	2007-09-28	Pharmaceutical composition having prpkinetic effect
EP1747205A4 (en)	2008-02-13	PHARMACEUTICAL COMPOSITIONS
GB0502792D0 (en)	2005-03-16	Pharmaceutical compositions
GB0400971D0 (en)	2004-02-18	Pharmaceutical compositions
GB0407351D0 (en)	2004-05-05	Pharmaceutical compositions
GB0411502D0 (en)	2004-06-23	Pharmaceutical compositions
GB0402799D0 (en)	2004-03-10	Pharmaceutical composition